erlotinib

Overview

Erlotinib is a small-molecule tyrosine kinase inhibitor used in oncology as a targeted therapy against the epidermal growth factor receptor (EGFR). By inhibiting EGFR signaling, erlotinib can reduce downstream pathways that promote tumor cell proliferation, survival, and migration. It is therefore commonly used as a reference EGFR inhibitor in medicinal chemistry and cancer pharmacology studies, especially in work focused on lung cancer and other EGFR-driven malignancies.

In recent biomedical research, erlotinib continues to serve both as a comparator drug and as a mechanistic probe for EGFR-dependent signaling. The publications provided here place it in studies of dual-target strategies, including EGFR/CDK-2 inhibition, EGFR/PARP-1 inhibition, and combination approaches with RAF inhibition or radiotherapy. These contexts reflect its role as a benchmark for potency and as part of broader efforts to improve Targeted Cancer Therapy in diseases such as colorectal carcinoma, pancreatic cancer, diffuse intrinsic pontine glioma, and lung cancer.

Focus of Latest Publications

Recent publications on erlotinib have focused on its role as an EGFR-targeted therapy in both clinical and preclinical settings, as well as on mechanisms of resistance and combination strategies intended to improve efficacy. In the randomized phase 2 BIOMEDE trial in diffuse intrinsic pontine glioma, erlotinib was tested with radiotherapy alongside everolimus and dasatinib in biomarker-selected patients. The study was stopped for futility, and overall survival from biopsy was not improved in the erlotinib arm compared with the control cohort. In a separate real-world study of EGFR-mutated metastatic non-small cell lung cancer, gefitinib/erlotinib was compared with osimertinib; the combined gefitinib/erlotinib group did not show inferior clinical effectiveness, although osimertinib had a better safety profile.

Several recent studies used erlotinib as a reference compound while developing new EGFR-directed agents. One report described fused pyrazolo[3,4-b]pyridine-linked isoxazoles and 1,2,3-triazoles that showed EGFR kinase inhibition and antiproliferative activity in lung cancer cell lines, with docking studies indicating interactions in the EGFR ATP-binding pocket comparable to erlotinib. Another study on dual PARP-1/EGFR inhibitors compared new boomerang-shaped compounds against erlotinib and olaparib, identifying a lead with dual inhibitory activity and apoptosis-inducing effects in MDA-MB-231 cells. A separate scaffold-optimization study of 1,2,4-triazolo[1,5-a]pyrimidines also used erlotinib as the EGFR reference in docking and enzymatic comparisons, supporting the development of dual EGFR/CDK-2 inhibitors for colorectal carcinoma.

Erlotinib resistance was also a major theme. A structure-based PHGDH inhibitor program reported that two novel compounds suppressed de novo serine biosynthesis and showed antiproliferative activity in PHGDH-overexpressing cells, including erlotinib-resistant PC9 and HCC827 lines; one compound enhanced antitumor efficacy in an erlotinib-resistant PC9 xenograft model when combined with erlotinib. In addition, a single-cell response analysis framework, scRADAR, identified candidate TGF-β-associated epithelial-to-mesenchymal transition signatures in erlotinib-associated resistant cell states, suggesting a possible resistance-associated program at single-cell resolution.

Key Publications

NEWJun scRADAR: Dissecting intratumoral drug response heterogeneity at single-cell resolution via mechanism-guided prototype routing. (PLoS computational biology, 2026, PMID 42361193): "Post hoc attribution analyses highlighted candidate TGF-β-associated epithelial-to-mesenchymal transition signatures in Erlotinib-associated Resistant-labeled states and cytoskeletal/metabolic response-associated signatures in BET-inhibitor-associated Resistant-labeled states."
NEWJun Structure-Based Design and Optimization of Novel PHGDH Inhibitors for Overcoming Erlotinib-Resistant Lung Cancer. (Journal of medicinal chemistry, 2026, PMID 42263187): "Notably, compounds 43 and 47 also demonstrated antiproliferative effects against erlotinib-resistant PC9 and HCC827 cell lines, exhibiting synergistic effects when combined with erlotinib."
Jun Molecular Boomerangs Against Cancer: Design, Synthesis, Biological Evaluation, and In Silico Study of Novel Dual PARP-1/EGFR Inhibitors. (Drug development research, 2026, PMID 42207930): "Compared with the reference medications erlotinib and olaparib, compound 3h showed the highest dual inhibition (EGFR IC50 = 1.62 μM and PARP-1 IC50 = 0.36 μM) in enzymatic experiments, demonstrating that these compounds effectively inhibited both EGFR and PARP-1."
Jun Lead Discovery via Scaffold Refinement: Structure-Guided Optimization of 1,2,4-Triazolo[1,5-a]Pyrimidines as Potent Dual EGFR/CDK-2 Inhibitors Targeting Colorectal Carcinoma. (Drug development research, 2026, PMID 42200498): "Leads 12c, 12i, and 22 demonstrated potent kinase inhibition, with 22 yielding a CDK-2 IC₅₀ of 0.03 μM (seliciclib: 0.02 μM), and 12c delivering an EGFR IC₅₀ of 0.12 μM (erlotinib: 0.01 μM)."
Apr Targeted therapies plus radiotherapy for diffuse intrinsic pontine glioma: the randomized phase 2 BIOMEDE trial. (Nature medicine, 2026, PMID 42032072): "...of epidermal growth factor receptor (EGFR) inhibitor erlotinib, mTOR inhibitor everolimus and multitargeted tyrosine kinase inhibitor dasatinib in combination with radiotherapy..."
Jun Synthesis and anti-lung cancer evaluation of fused pyrazolo[3,4-b]pyridine linked isoxazoles and 1,2,3-triazoles: PEG-400 mediated one-pot reaction under microwave irradiation. (Bioorganic chemistry, 2026, PMID 41795438): "comparable to that of the reference drug, erlotinib."
Feb Comparison of first and third generation EGFR-TKIs for the treatment of advanced non-small cell lung cancer: A real-world study. (Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2025, PMID 39962869): "The purpose of our research was to evaluate and compare the superiority of osimertinib over gefitinib/erlotinib in terms of clinical effectiveness and safety."